Mentrik Biotech, LLC is a private biopharmaceutical company that was incorporated in December 2010 and is headquartered in Dallas, TX. The goal of Mentrik Biotech is to optimize oncology-based therapeutics to treat patients with significant unmet medical need. Mentrik is developing AME-133v, a humanized, next-generation anti-CD20 monoclonal antibody. It is engineered for enhanced affinity to CD20 and increased antibody-dependent cell-mediated cytotoxicity (ADCC), and designed for improved treatment for low-affinity Fc’RIIIa polymorphisms. Phase I/II trials in follicular lymphoma have been conducted in the US and Japan, and a Phase I trial in US rheumatoid arthritis patients. Continued Phase III development in relapsed follicular lymphoma patients is underway. Many patients relapse following current available treatments and a significant need for new effective treatment exists. Additional development in other oncology and rheumatology indications will also be pursued. Mentrik Biotech aims to develop convenient, potent and cost-effective anti-cancer molecules to enhance treatment options for patients and fulfill unmet therapeutic needs. By utilizing engineered antibodies and next-generation molecules, Mentrik seeks to fulfill an unmet need in patient therapeutics by enhancing treatment options and optimizing clinical benefit. By developing more potent therapeutics, Mentrik can facilitate improved treatment through less frequent dosing, decreased drug administration, and create subcutaneous formulations for easier patient administration. Mentrik also aims to support healthcare in developing countries, supplying superior antibodies to patients where treatment is lacking or non-existent at a very low cost.